Prostate MR Imaging in 2011: Current Role in Staging and Surveillance; Nov. 28, 8:30am-10:00am

TriMed Staff | | Health Imaging | Diagnostic Imaging
A team of researchers will review the basics of prostate MR imaging, including the limitations of current therapeutic approaches; prostate cancer care guidelines; indications for prostate MR imaging and its role in diagnosis, management and biopsy.

When: Monday, Nov. 28, 8:30-10:00am
Where: S406B

Speaker information:
Peter L. Choyke, MD, chief senior clinician molecular imaging, National Cancer Institute, Bethesda, Md.
Masoom Haider, MD, clinician scientist, Ontario Institute for Cancer Research, Toronto
Neil M. Rofsky, MD, chief MRI, Beth Israel Deaconess Medical Center, Boston

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.